COVID-19 antibodies on trial

With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, Nature Biotechnology asked a group of experts to comment on the challenges and timelines for these products.

Detalles Bibliográficos
Autor principal: DeFrancesco, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Q&A
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576980/
https://www.ncbi.nlm.nih.gov/pubmed/33087898
http://dx.doi.org/10.1038/s41587-020-0732-8
Descripción
Sumario:With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, Nature Biotechnology asked a group of experts to comment on the challenges and timelines for these products.

Ejemplares similares